Cholinergic Agonists & Anticholinesterases

Foundational principles covering parasympathetic and sympathetic neurotransmission, receptor mechanisms, clinical pharmacology, toxicities, and emergent crises of the autonomic nervous system.

Learn

The cholinergic limb of the autonomic nervous system relies on acetylcholine (ACh) to stimulate postganglionic muscarinic and ganglionic nicotinic receptors. Direct agonists such as bethanechol directly activate detrusor muscarinic receptors to overcome urinary atony, whereas indirect agents prevent enzymatic clearance by acetylcholinesterase to amplify physiological signaling.

Key Clinical Concepts & Topics

Acetylcholine Neurotransmission & Receptor Subtypes

Parasympathetic & Ganglionic Signaling: Acetylcholine serves as the universal neurotransmitter across preganglionic fibers (myelinated) acting on nicotinic N_N receptors in ganglia, and postganglionic parasympathetic fibers (unmyelinated) acting on muscarinic receptors (M₁, M₂, M₃).
Muscarinic GPCR Signaling: M₁, M₃, M₅ couple to Gq (IP₃/DAG intracellular calcium cascade) promoting smooth muscle contraction and gland secretion; M₂ couples to Gi (inhibiting adenylyl cyclase) slowing SA node firing and AV conduction.
Nicotinic Ionotropic Channels: N_N (autonomic ganglia) and N_M (neuromuscular junction) are pentameric ligand-gated Na+/K+ channels mediating rapid membrane depolarization.

Direct-Acting Muscarinic Agonists

Bethanechol Mechanics: Resists AChE hydrolysis; selectively activates M₃ detrusor receptors to stimulate bladder contraction and relax internal sphincters. Indicated for postoperative non-obstructive urinary retention and neurogenic bladder atony.
Bethanechol Safety Warning: Never administer via IV or IM routes; rapid systemic bolus causes massive vasodilation, severe bradycardia, circulatory collapse, and lethal bronchospasm.
Pilocarpine Mechanics: Topical ophthalmic agonist stimulating pupillary sphincter (miosis) and ciliary muscle contraction, opening the trabecular meshwork to promote aqueous humor drainage in open-angle and acute angle-closure glaucoma. Oral form treats severe xerostomia.

Reversible & Irreversible Anticholinesterases

Reversible Agents: Neostigmine and Pyridostigmine are charged quaternary amines (do not cross BBB) used for myasthenia gravis and reversing non-depolarizing neuromuscular blockers. Donepezil and Rivastigmine are tertiary amines that cross BBB to slow Alzheimer's cognitive decline.
Organophosphate Toxicity & Aging: Organophosphates (malathion, parathion, sarin) phosphorylate the serine hydroxyl residue of AChE. Over hours, covalent alkyl-phosphate bonds undergo spontaneous dealkylation ('aging'), rendering inhibition irreversible.
Emergency Antidote Management: Titrate massive doses of IV atropine immediately to block lethal muscarinic secretions and bradycardia. Administer pralidoxime (2-PAM) before aging occurs to nucleophilically displace the phosphate group and reactivate AChE.

Edrophonium (Tensilon) Test & Crisis Differentiation

Myasthenic Crisis Mechanics: Caused by disease flare or underdosing of anticholinesterases (insufficient ACh at junction). Pupillary exam shows mydriasis or normal pupils; secretions are normal/dry. Edrophonium challenge produces immediate temporary improvement in muscle strength.
Cholinergic Crisis Mechanics: Caused by anticholinesterase overdose (excessive ACh accumulation causing depolarizing neuromuscular block). Exam shows pinpoint pupils (miosis), profuse salivation, sweating, hyperactive bowel sounds, and fasciculations. Edrophonium challenge causes worsening paralysis and cardiovascular collapse.

Read full notes

These notes add mechanisms and relationships. Read one topic at a time.

Myasthenic versus cholinergic crisis

Distinguishing myasthenic crisis from cholinergic crisis is critical in unstable respiratory failure. While both present with severe muscle weakness, myasthenic crisis improves with anticholinesterase administration, whereas cholinergic crisis represents depolarizing neuromuscular toxicity requiring immediate drug withdrawal and atropine administration.

Acetylcholine, muscarinic, and nicotinic receptors

Acetylcholine is the transmitter at all autonomic ganglia, at parasympathetic postganglionic endings, and at the skeletal neuromuscular junction. Muscarinic receptors (M1–M5) are G-protein-coupled: M1, M3 and M5 use Gq; M2 uses Gi and slows the heart. Nicotinic receptors are ligand-gated ion channels: NN at ganglia and NM at skeletal muscle. Direct agonists bind those receptors. Indirect agonists (anticholinesterases) stop acetylcholinesterase from splitting ACh into choline and acetate, so more ACh remains in the cleft.

Direct agonists: bethanechol and pilocarpine

Bethanechol is a direct muscarinic agonist that resists acetylcholinesterase. It is used for postoperative and neurogenic non-obstructive urinary retention by activating detrusor muscarinic receptors. Parenteral injection is avoided because a rapid systemic bolus can cause severe bradycardia, hypotension, and bronchospasm. Pilocarpine is a muscarinic agonist used topically for glaucoma (miosis and ciliary contraction that help aqueous outflow) and orally for dry mouth. Methacholine is used as an airway challenge test.

Anticholinesterases, ageing, and pralidoxime

Reversible anticholinesterases include neostigmine and pyridostigmine (charged; they stay out of the brain and are used for myasthenia gravis and to reverse non-depolarising neuromuscular block) and donepezil, rivastigmine, and galantamine (they enter the brain and are used in Alzheimer disease). They do not cure Alzheimer disease. Organophosphates phosphorylate acetylcholinesterase; after hours the bond ‘ages’ and inhibition becomes irreversible. Emergency treatment uses atropine for muscarinic features and pralidoxime before ageing to regenerate the enzyme.

Edrophonium and the two crises

Myasthenic crisis is too little acetylcholine at a damaged neuromuscular junction; strength improves if a short-acting anticholinesterase such as edrophonium is given. Cholinergic crisis is too much acetylcholine from anticholinesterase overdose, with muscarinic signs (miosis, salivation, diarrhoea) and a depolarising block; the same edrophonium dose makes weakness worse. That worsening means stop the cholinesterase inhibitor and give atropine. Both crises can present as respiratory failure, so the distinction is the check in this section.

Explore

Core Concepts Defined

Acetylcholine (ACh): The primary neurotransmitter of the parasympathetic nervous system (PNS), somatic motor endplates, and all autonomic ganglia.
Muscarinic Receptors (M₁–M₅): G-protein coupled receptors (M₁ through M₅) located on cardiac muscle, smooth muscle, and secretory glands that mediate parasympathetic 'rest and digest' responses.
Nicotinic Receptors (N_N, N_M): Ligand-gated ion channels located at autonomic ganglia (N_N) and the skeletal neuromuscular junction (N_M) that mediate depolarization and skeletal muscle contraction upon ACh binding.
Acetylcholinesterase (AChE): The hydrolytic enzyme situated within synaptic clefts responsible for cleaving ACh into inactive choline and acetate to terminate signaling.
Direct-Acting Cholinergic Agonist: A synthetic or natural agent that binds directly to muscarinic or nicotinic receptors to mimic endogenous ACh (e.g., bethanechol, pilocarpine).
Indirect-Acting Cholinergic Agonist: An agent that inhibits AChE, preventing the breakdown of endogenous ACh and elevating synaptic neurotransmitter concentrations.
Myasthenic Crisis: An acute, life-threatening exacerbation of myasthenia gravis caused by severe ACh receptor deficiency or clinical underdosing of anticholinesterase therapy, resulting in severe respiratory failure.
Cholinergic Crisis: Severe flaccid muscle paralysis and excessive parasympathetic discharge caused by excessive anticholinesterase medication or organophosphate poisoning (depolarizing neuromuscular blockade).
SLUDGE / DUMBELS Mnemonics: Clinical mnemonics characterizing excessive muscarinic discharge: Salivation, Lacrimation, Urination, Defecation, Gastrointestinal cramping, Emesis / Diarrhea, Urination, Miosis, Bronchospasm, Emesis, Lacrimation, Salivation.

Go deeper: clinical case study

Clinical Case Study 2.1: The Deteriorating Myasthenic Patient

A 42-year-old female with generalized myasthenia gravis is brought to the emergency department with acute dyspnea, shallow respirations, and marked generalized limb weakness. Her family reports she had doubled her pyridostigmine dosage over the preceding 48 hours to overcome progressive fatigue. Physical exam reveals profuse oral salivation, cool diaphoretic skin, bilateral pinpoint pupils, and diffuse abdominal fasciculations.

Mechanistic Breakdown & Clinical Analysis

Pathology Identification: The constellation of pinpoint pupils (miosis), excessive secretions (salivation, sweating), and muscle fasciculations points directly to cholinergic crisis secondary to anticholinesterase overdose, not myasthenic crisis.
Cellular Action: Excessive synaptic acetylcholine persistently depolarizes the nicotinic N_M receptors at the skeletal neuromuscular junction. Because the motor endplate cannot repolarize, flaccid neuromuscular paralysis results, causing diaphragmatic failure.
Immediate Management: Withhold all anticholinesterase medications immediately. Secure the airway via endotracheal intubation and mechanical ventilation. Administer intravenous atropine to block muscarinic hyperactivity, dry secretions, and resolve bronchospasm.